New Microbiologica最新文献

{"title":"Candida krusei pericarditis: A case report and review of the literature.","authors":"Ahmed Qaedi, Umran Elbahr, Gülcan Abalı, Burcu Çakar, Orhan Şencan, Suha Hejres, Oguz Resat Sipahi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>A 66-year-old female, a known case of endometrial serous carcinoma, presented with a history of poor oral intake. Elevated C-reactive protein was identified, and an echocardiogram showed evidence of large circumferential pericardial fluid with maximum diameter measuring 4.4 cm. Further analysis of the pericardial fluid revealed growth of Candida krusei. Treatment was initiated with caspofungin 150mg intravenously once daily for 28 days, followed by oral maintenance therapy with voriconazole for 10 days. No relapse or re-infection was observed during 10 days of follow-up. A literature search was performed, which demonstrated that Candida albicans is the most encountered Candida spp. associated with acute pericarditis. Additionally, the following risk factors were observed, including history of major surgery, COVID-19 infection, and use of broad-spectrum antibiotics. This article presents a unique case of acute pericarditis caused by C. krusei. It highlights the importance of identifying the etiology in immunocompromised cohorts and emphasizes the role of establishing formative treatment guidelines for the management of Candida spp. pericarditis.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 4","pages":"355-357"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular characterization and survival of extended-spectrum β-lactamase-producing clinical strains of Klebsiella pneumoniae isolated in Mostar, Bosnia and Herzegovina.","authors":"Tanja Petrović, Marija Tonkić, Ana Maravić, Mia Dželalija, Željana Fredotović, Jasna Hrenović, Sanja Jakovac, Doris Martinović Rizikalo, Ivana Goić-Barišić","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The aim of this retrospective study was to investigate the molecular characteristics and survival ability of clinical isolates of extended-spectrum β-lactamase (ESBL)-producing strains of Klebsiella pneumoniae (K. pneumoniae) in a hospital setting. ESBL-producing K. pneumoniae clinical isolates were collected from hospitalized patients at the University Clinical Hospital of Mostar, Bosnia and Herzegovina. Identification and antibiotic susceptibility tests were performed according to established laboratory methods and Clinical and Laboratory Standards Institute standards. Phenotypic identification of the isolates was confirmed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Minimum inhibitory concentrations were determined using the Vitek® 2 Compact System. Clonal relationships between the different isolates were studied using pulsed-field gel electrophoresis. Molecular characterization of ESBL-coding genes was performed using multiplex polymerase chain reaction. The survival and pellicle formation abilities of ESBL-producing K. pneumoniae isolates were also investigated. Among 471 isolated K. pneumoniae strains, 149 isolates (31.6%) were ESBL-producing. The bla genes encoding CTX-M-1-group ESBLs were identified in almost all isolates, with the majority carrying blaCTX-M-15. Two isolates contained blaCTX-M-3. All isolates carried blaTEM-1. The blaSHV genes identified were blaSHV-1, blaSHV-5, blaSHV-11, and blaSHV-28. Six isolates harbored blaOXA-1. ESBL-producing K. pneumoniae strains survived on dry cotton for up to 49 days.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 4","pages":"337-343"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HIV cure-related research: where we stand and where we go.","authors":"Martina Ranzenigo, Antonella Castagna, Camilla Muccini","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This review outlines the progress and challenges in HIV cure research, with a particular focus on gene therapy, latency-reversing agents (LRAs), immunotherapy, and stem cell transplants. The objective of these advances is to achieve either a sterilizing or a functional cure, whereby the virus is either eradicated or controlled without the need for ongoing treatment. Gene editing tools, such as CRISPR-Cas9, have demonstrated the potential to remove HIV DNA from cells. LRAs, on the other hand, aim to reactivate latent virus, thereby rendering it susceptible to treatment or immune clearance. Immunotherapy, including therapeutic vaccines and broadly neutralizing antibodies, aims to enhance the immune response to HIV. However, achieving long-term suppression without antiretroviral therapy remains a significant challenge. Stem cell transplants have resulted in instances of remission; however, the methodology is intricate, perilous, and viable solely for patients with particular medical requirements. Each approach encounters challenges pertaining to safety, administration, and accessibility. In sum, while considerable advancement has been achieved, a combination of therapeutic strategies and further innovations are imperative for the development of a sustainable, widely accessible HIV cure.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 4","pages":"303-310"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A serious hepatitis E case in the city of Rieti (Lazio, Italy): correlation with a 2019 cluster suggests a resident hepatitis E virus strain; a case report.","authors":"Mauro Zaccarelli, Claudia Minosse, Silvia Pauciullo, Massimiliano Scuderi, Fabio Gemelli, Giuseppe Tacchi, Giovanna Giacchetti, Mauro Marchili, Valentina D'Ovidio, Anna Rosa Garbuglia","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Hepatitis E is generally considered a mild disease, but severe cases are also observed. In high-income countries, most hepatitis E cases are due to HEV genotype 3 and are linked mainly to the consumption of pork or wild boar meat, but data on the correlation of viral variants and hepatitis severity are still preliminary. We described a serious acute hepatitis E (Genotype 3e) case observed in the city of Rieti (Lazio region, Italy), and compared it with previous cases found in the same geographical area. Phylogenetic analysis of open reading frame 2 (ORF2) showed that the HEV strain of the patient in Rieti is closely related to those identified in the acute HEV hepatitis outbreak in 2019. Our data suggest the need to strengthen surveillance and prevention against HEV infection and investigation of pathogenicity linked to specific HEV variants.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 4","pages":"358-362"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clarithromycin-resistant Helicobacter pylori in Ankara, Turkey: Detection by real-time PCR in formalin-fixed paraffin-embedded gastric biopsy samples.","authors":"Betül Yüzügüldü, Yusuf Üstün, Sehbal Arslankoz, Eylül Beren Tanık, Ayfer Bakır, Murat Alper","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Choosing the appropriate treatment regimen for Helicobacter pylori (Hp) depends on knowing or predicting regional antibiotic resistance rates. In this study, we aimed to determine the frequency of Hp and clarithromycin (Cla) resistance rates by PCR analysis in formalin-fixed paraffin-embedded (FFPE) gastric biopsies of patients diagnosed with gastritis. Hp DNA and Hp Cla resistance (ClaR) were analyzed by PCR method. Diagnostic examination of gastric biopsy samples was evaluated according to the Updated Sydney System. Hp positivity was detected in 68 of 149 samples (45.6%). ClaR was detected in 29 Hp-positive samples (42.6%). A decrease in the resistance rate to Cla in HP was observed with increasing age (p = 0.08). The risk of resistance was higher in women (OR 1.1, 95% CI: 0.41-2.90, p = 0.86). The ClaR was higher in the 18-40 age group than in the over-60 age group (OR 5.5, 95% CI: 1.16-26.14, p = 0.03). The ClaR rate was found to be 42.6% by molecular method, indicating that classical triple therapy containing Cla is not a suitable option. Since resistance may vary according to geographical regions and years, regional studies with large populations are needed to determine antibiotic resistance rates before treatment planning.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 4","pages":"324-329"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary Brain Abscess Due to Nocardia cyriacigeorgica in a patient with renal transplantation: Case Report.","authors":"Gamze Altan, Alper Tabanli, Gulsen Ozgenc, Gulfem Ece","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Nocardia is an opportunistic pathogen affecting immunosuppressed patients. This case report aims to present a primary brain abscess due to Nocardia cyriacigeorgica in an immunosuppressed kidney transplant patient. An 48-year-old female patient presented to the emergency department with complaints of sudden onset of headache and confusion. The patient had a history of renal transplantation (one year previously). CT scans were performed due to blurred consciousness, with an appearance compatible with a cystic necrotic lesion with haemorrhagic densities around the left parietooccipital. Since the patient was immunosuppressive, broad-spectrum antibiotics were started. All necessary medical examinations were completed immediately and the patient underwent a transcranial operation. The abscess fluid and lesion were completely removed along with the capsule. The surgical material was sent to the Microbiology laboratory. The culture reported Nocardia cyriacigeorgica as the pathogen. The patient died on the 17th postoperative day due to clinical presentation of DIC. As a conclusion, considering CNS nocardiasis, routine contrast-enhanced brain imaging and rapid microbiological diagnosis are of vital importance, especially in immunosuppressed patients. Resistance was largely species-specific for Nocardia spp. Identification of Nocardia at the species level and early initiation of treatment with the most appropriate drug according to its antimicrobial susceptibility will lead to success in treatment and reduce mortality rates.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 4","pages":"363-367"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current Status of Alkhurma Hemorrhagic Fever Virus Infection: Future Concerns and Considerations.","authors":"Nada Mohammed Aljuaid, Magdah Ali Ganash, Sayed Sartaj Sohrab, Esam Ibraheem Azhar","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Alkhurma hemorrhagic fever virus (AHFV), a novel flavivirus, was first identified in the Alkhurma district, Jeddah, Saudi Arabia in 1995. It belongs to the Orthoflavivirus genus of the Flaviviridae family, and can be transmitted through contact with infected livestock animals or via tick bites. The initial symptoms resemble influenza along with hemorrhagic manifestations, which are less common but not unheard of in cases similar to encephalitis. Unfortunately, there are no specific treatments or vaccines available for AHFV infection. This review provides insights into the epidemiology, prevalence, transmission, clinical manifestations, diagnosis, control strategies, and preventive measures for AHFV disease in the Kingdom of Saudi Arabia.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 4","pages":"314-323"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical analysis of meningitis in neonates infected with ESBL-producing Escherichia coli: a retrospective study.","authors":"Weitang Huang, Liuqing Ye, Guangming Chen, Qiongdan Fan, Hanbing Yu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli are widely distributed in the community. Notably, ESBL-producing E. coli have high-frequency early mother-to-child transmission. The current study determined the treatment and intervention measures among neonates with ESBL-producing E. coli meningitis. Five neonates (4 males and 1 female) with meningitis caused by ESBL-producing E. coli admitted to our center from June 2020 to July 2023 were retrospectively reviewed. The clinical characteristics and treatment effects were analyzed. There were 4 cases of early- onset sepsis and 1 case of a catheter-related bloodstream infection. Four of 5 cases were premature infants with gestational ages between 27 and 33 weeks. The clinical manifestations included fevers (n=5), lethargy (n=5), dyspnea (n=4), and microcirculation disorders (n=4). Meropenem was infused intravenously in 2 patients with a median duration of 120.5 d (range, 98-143 d) at an early dose of 40 mg/kg every 12 h and an extended infusion. Three patients were infused with 40 mg/kg every 8 h for a median duration of 28 d (range, 21-61 d). Two neonates had recurrent illnesses, three neonates developed hydrocephalus, one neonate had a cerebral hemorrhage, and one neonate had convulsions during treatment. The follow-up results showed 4 neonates had normal neuromotor development and 1 neonate had a 2-month lag in neuromotor development. Maternal perinatal infections, premature delivery, and catheter-related bloodstream infections are high-risk factors for ESBL-producing E. coli meningitis. Children with fevers and lethargy should be monitored closely. ESBL-producing E. coli infections in children with meningitis are prone to recurrences and secondary hydrocephalus. Attention should be paid to ensuring the correct high dose of the antibiotic.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 4","pages":"330-336"},"PeriodicalIF":1.5,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143494851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Pharmacology of the Single Tablet Regimen Bictegravir/Emtricitabine/Tenofovir Alafenamide in the evolving era of antiretroviral therapies.","authors":"Giovanni Di Perri, Stefano Bonora","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In this fast-evolving era of antiretroviral chemotherapy, the single-tablet regimen (STR) BIC/FTC/TAF, an oral regimen including a potent INSTI (strand-transfer integrase inhibitors) like Bictegravir plus two different NRTIs (Nucleoside Reverse Transcriptase Inhibitors), is increasingly challenged by new oral combinations. Furthermore, long-acting injectable drugs have also been developed and others are being under development. Notably, no new STR consisting of two NRTIs plus a 3rd drug like an INSTI are in the industrial pipeline. However, many People with HIV (PWH) still need potent multidrug regimens, especially those newly diagnosed with advanced HIV (defined late presenters), which represent over 50% of new infections. The asymmetrical comparison between a potent STR like BIC/FTC/TAF and new combinations is difficult to make. By comparing the STR BIC/FTC/TAF, the most representative of potent multi-drug regimens, with all approved new options, we can distinguish some features that are worthy of attention. The stronger genetic barrier and the better forgiveness resulting from BIC/FTC/TAF is self-evident, with the extra coverage here provided by the remarkable pharmacologic properties of TAF, consisting of great diffusion into target cells, long persistence at high concentration, and a much lower plasma exposure. On the pharmacokinetic side, the main difference is between oral and long-acting injectable regimens. Pk of long-acting injectables consists of a single peak (followed by a slow decrease in drug concentration), while with oral regimens daily C max - C trough fluctuations take place instead. The latter property of oral regimens should be taken into account whenever the Pk exposure is suboptimal, as it might allow inhibition of the growth of quasi-species that are less sensitive. The choice of the new combinations including long acting injectables instead of the STR BIC/FTC/TAF might be made for sure for several reasons, but compared to the past when combinations included TDF, toxicity by TAF is no longer an issue today. The size of the tablet and its net weight may be disproportional to the number of drugs, as there are multidrug regimens like the STR BIC/FTC/TAF whose weight may be lower than those of the new oral combinations INSTI-based for both naive and switching PWH. Although multi-drug regimens like the STR BIC/FTC/TAF are no longer in development, their use in clinical practice will still remain substantial for a long time and knowledge of their properties is necessary to properly select the most appropriate regimens for PWH.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 3","pages":"243-250"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One stage extraction and reimplantation of ICD/PM in patients with CIED related endocarditis and spondiloscitis due to E. faecalis treated with double beta-lactam combination: ampicillin plus ceftobiprole.","authors":"Maria Lucia Narducci, Davide Pecori, Massimo Imazio, Luca Rebellato, Monica Geminiani, Giulia Bontempo, Luca Martini, Simone Giuliano, Carlo Tascini","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The time of re-implantation of removed CIED for local infection or endocarditis has been debated because no randomized studies are available. Many authors prefer to delay reimplantation to the time of blood culture negative or clinical stability. In this case report we describe the case of E. faecalis CIED endocarditis treated with the combination ampicillin plus ceftobiprole and one-stage removal and re-implantation with early follow-up without relapse of infection. In case of E. faecalis infection, we hypothesize that ampicillin plus ceftobiprole combination might have bactericidal and anti-biofilm activity, therefore allowing one state re-implantation without relapse.</p>","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 3","pages":"292-294"},"PeriodicalIF":1.5,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}